Prevalence of Atrial Fibrillation in Cryptogenic Stroke With Patent Foramen Ovale Closure (PFO-AF) Study

Status: Active_not_recruiting
Location: See all (4) locations...
Intervention Type: Device, Procedure
Study Type: Observational
SUMMARY

This study aims to assess the incidence of atrial fibrillation (AF), documented using data recorded by an implantable Holter monitoring device (Reveal Linq, Medtronic) within 2 years after percutaneous closure of patent foramen ovale for cryptogenic stroke.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Adult patients (aged \>18 years)

• with an indication for percutaneous closure of PFO due to cryptogenic stroke, with indication validated by a cardio-neurological team.

• patients must provide written informed consent

• patients must be affiliated to a social security regime or be a beneficiary thereof.

Locations
Other Locations
France
University Hospital Besancon
Besançon
CHU Lyon - Hôpital Louis Pradel
Bron
CHU Dijon
Dijon
CHU Grenoble
Grenoble
Time Frame
Start Date: 2021-07-05
Completion Date: 2025-12-31
Participants
Target number of participants: 250
Treatments
Patients planned for percutaneous PFO closure
Patients will undergo implantation of a Holter device (Reveal Linq Medtronic) 2 months prior to percutaneous PFO closure. Devices will be monitored by telemonitoring until the PFO closure procedure, and at 2, 12 and 24 months after the procedure.
Sponsors
Leads: Centre Hospitalier Universitaire de Besancon

This content was sourced from clinicaltrials.gov